MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Aandelen Lijst・Geron Corp

Geron Corp

Gesloten

SectorGezondheidszorg

1.74 -0.57

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.72

Max

1.83

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -29M
Verkoop	788K 48M
Winstmarge	-60.11
Werknemers	258
EBITDA	-14M -24M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+85.71% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-8.9M 1.1B
Vorige openingsprijs	2.31
Vorige sluitingsprijs	1.74

Nieuwssentiment

By Acuity

32%

68%

88 / 349 Rangschikking in Healthcare

Geron Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2026, 17:26 UTC

Belangrijke Nieuwsgebeurtenissen

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 apr 2026, 23:55 UTC

Marktinformatie

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Market Talk Roundup: Latest on U.S. Politics

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 apr 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:15 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 apr 2026, 23:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 apr 2026, 23:03 UTC

Marktinformatie

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 apr 2026, 22:58 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

7 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 apr 2026, 19:45 UTC

Marktinformatie

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 apr 2026, 19:17 UTC

Belangrijke Nieuwsgebeurtenissen

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 apr 2026, 19:16 UTC

Marktinformatie

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Global Energy Roundup: Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 apr 2026, 18:41 UTC

Acquisities, Fusies, Overnames

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 apr 2026, 18:40 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 apr 2026, 18:39 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 apr 2026, 18:24 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 17:08 UTC

Marktinformatie

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 apr 2026, 16:21 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Geron Corp Prognose

Koersdoel

By TipRanks

85.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.25 USD 85.71%

Hoogste 5 USD

Laagste 1 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Geron Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Geron Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

88 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.